<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01626560</url>
  </required_header>
  <id_info>
    <org_study_id>daptocina</org_study_id>
    <nct_id>NCT01626560</nct_id>
  </id_info>
  <brief_title>The Effects of Daptomycin and Cytokines Production in Comparison With Vancomycin</brief_title>
  <official_title>Effects of Daptomycin in the Levels of IL-1, IL-6 and TNF in Patients With Complicated Cellulitis/Erisipela in Comparison With Vancomycin or Oxacillin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Evangelico de Curitiba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Evangelico de Curitiba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary: To determine the influence of daptomycin on inflammatory cytokine (IL-1, TNF and
      IL-6) for the treatment of complicated cellulitis/erysipela compared with alternative
      treatment (vancomycin or oxacillin). Secondary: To evaluate the clinical outcome of both
      groups according to levels of the cytokines evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cytokine levels</measure>
    <time_frame>AUC will be calculated with multiple time points over a period of 14 days (0, 4, 8, 12 , 16, 24, 48, 72, 96, 120 and 168 hours post‐dose)</time_frame>
    <description>The results of cytokine levels will be evaluated after completion of antibiotic therapy, when testing will take place in the laboratory. Thus the measurement of cytokines will not be used to evaluate the clinical outcome.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Cellulitis</condition>
  <arm_group>
    <arm_group_label>Daptomicina</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daptomycin</intervention_name>
    <description>daptomycin 4-6mg/kg qd 10 - 14 days</description>
    <arm_group_label>Daptomicina</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Vancomycin 1g q12h 10 - 14 days</description>
    <arm_group_label>Vancomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Eligible patients will be age between 18 and 65 who required hospitalization and
             parenteral antimicrobial therapy

          2. Clinical documentation of cellulitis / erysipela

          3. Documentation of a minimal surface area 75 cm2 based on the length and / or width of
             the redness, swelling and / or induration

          4. Documented fever, defined as oral or tympanic temperature greater than or equal to 38
             ° C

        Exclusion Criteria:

          1. Infections and other minor addition of erysipelas / cellulitis

          2. Any recent use of antibacterial drug therapy (systemic or topical antibacterial drugs
             within 14 days of enrollment)

          3. Patients with clinical conditions that alter the interpretation of the primary outcome
             as patients with neutropenia or compromised immune function, as HIV infection,
             autoimmune disorders, use of corticosteroids.

          4. Patients with known or suspected osteomyelitis.

          5. Patients with suspected or confirmed septic arthritis.

          6. Patients with complicated skin infections, such as diabetic foot infections. 7.
             Chronic use of antipyretic drugs (eg, daily use of naproxen).

        8. Less than 18 years of age. 9. pregnancy 10. Patients with mixed infections of
        Gram-negative or be deleted since the therapy of gram-negative can influence the levels of
        cytokines.

        11. Patients with renal clearance &lt;30 mL / min. 12. Patients who are not susceptible to
        daptomycin or vancomycin. 13. Allergy to study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitário Evangelico de Curitiba</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80730150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2012</study_first_submitted>
  <study_first_submitted_qc>June 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2012</study_first_posted>
  <last_update_submitted>March 19, 2015</last_update_submitted>
  <last_update_submitted_qc>March 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Evangelico de Curitiba</investigator_affiliation>
    <investigator_full_name>Felipe Francisco Bondan Tuon</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Daptomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

